^
    Back
    Association details:
    Biomarker:GBP5 overexpression
    Cancer:Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Inflamm Res
    Title:

    GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment

    Published date:
    09/20/2023
    Excerpt:
    Patients in each cohort were devided into two groups with high (GBP5-High) and low (GBP5-Low) expression of GBP5. In both cohorts, the GBP5-High population had a higher proportion of patients that responded well to immunotherapy (responders) (p < 0.05).
    DOI:
    https://doi.org/10.2147/JIR.S401430